Generation Bio Begin Period Cash Flow Over Time
| GBIO Stock | USD 1.08 0.08 6.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Generation Bio Performance and Generation Bio Correlation. Generation |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.28 | Quarterly Revenue Growth 2.52 | Return On Assets (0.19) | Return On Equity (0.86) |
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Begin Period Cash Flow Analysis
Compare Generation Bio and related stocks such as Monte Rosa Therapeutics, Nkarta Inc, and Lyell Immunopharma Begin Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 9.2 M | 42.9 M | 351.4 M | 60.2 M | 102.4 M |
| NKTX | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 8 M | 20.9 M | 97.1 M | 62.9 M | 40.2 M | 44.5 M |
| LYEL | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 130.3 M | 98.5 M | 140.9 M | 294.3 M | 123.8 M | 173.3 M |
| SANA | (816 K) | (816 K) | (816 K) | (816 K) | (816 K) | (816 K) | (816 K) | (816 K) | (816 K) | 31.4 M | 81.8 M | 126.9 M | 261.8 M | 187.3 M | 126.2 M |
| KRON | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 10.2 M | 32.6 M | 250 M | 200.3 M | 78 M | 105 M |
| ERAS | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 29.6 M | 65.7 M | 360.9 M | 284.6 M | 172.7 M |
| CCCC | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 17 M | 38.9 M | 93.1 M | 184.3 M | 79.4 M | 33 M | 31.4 M |
| EWTX | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 23.7 M | 104.9 M | 15.6 M | 22 M | 38.4 M |
| IPSC | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 44.1 M | 27.7 M | 58.2 M | 86.2 M | 54.5 M |
| PASG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24.9 M | 158.9 M | 135 M | 129 M | 34.6 M | 32.9 M |
| STOK | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.9 M | 105.6 M | 222.7 M | 287.5 M | 145.5 M | 114.1 M | 138.1 M |
| NUVB | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 137.9 K | 3.5 M | 29.8 M | 132.4 M | 101.1 M | 58.7 M |
| STTK | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 31.6 M | 7 M | 157.9 M | 92.3 M | 47.4 M | 67.7 M |
Generation Bio and related stocks such as Monte Rosa Therapeutics, Nkarta Inc, and Lyell Immunopharma Begin Period Cash Flow description
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.My Equities
My Current Equities and Potential Positions
| Generation Bio Co | GBIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.08
Check out Generation Bio Performance and Generation Bio Correlation. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Generation Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.